SpinalCyte hopes CybroCell will usher in era of innovative spine treatment — 5 takeaways

Spinal Tech

SpinalCyte, a tissue engineering technology company based in Houston, has announced the enrollment of the first patient to partake in a study for the development of CybroCell.

Here are five things to know:

 

1. SpinalCyte's work aims to regrow spinal disc nucleus using human dermal fibroblasts.

 

2. The CybroCell is the first dermal fibroblast cell product aimed to treat degenerative disc diseases.

 

3. According to Pete O'Heeron, CEO of SpinalCyte, the groundbreaking study will be the "first time a human patient will receive dermal fibroblasts for treatment of degenerative disc disease."

 

4. All preclinical trials showed significant growth and development of the spinal disc nucleus, and more positive signs.

 

5. SpinalCyte hopes this development further paves the way for alternative treatments instead of surgery.

 

6. Once the trial begins, 18 patients between the ages of 18 and 85 will be administered CybroCell and monitored for a year.

 

7. SpinalCyte's goal is to reduce pain, improve function, and regenerate damaged discs with CybroCell.

 

More articles on spine devices:

Bioactive bone graft substitutes for spinal fusion — Key thoughts from Dr. Hyun Bae

SpineGuard® receives FDA clearance to market its DSG™ integration module for making pedicle screws “smart”

WishBone Medical to open its doors in Indiana — 5 highlights

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers